Sibutramine Hydrochloride

Sibutramine Hydrochloride Monohydrate for Obesity Treatment

Sibutramine Hydrochloride belongs to a new generation of weight management drugs. Sibutramine hydrochloride monohydrate, an obesity treatment pill, aids in the long-term management of weight control when used as an adjunct to diet and exercise. The European Union has approved the use of Sibutramine Hydrochloride as a continuous obesity treatment drug for a period up to 1 year which has now received an extended clearance of 2 years. When Sibutramine Hydrochloride Monohydrate is added to a strict diet and exercise regimen which also include positive lifestyle modifications, the results are 3-5 times more effective, that is 5% more weight maintenance is achieved. Indicated for use in obese patients, Sibutramine Hydrochloride is generally administered to patients with a BMI >30 kg/m2 as well as overweight patients with a BMI >27 kg/m2 who present with obesity-related risk factors such as type 2 diabetes or dyslipidaemia.

Benefits of Sibutramine Hydrochloride

Sibutramine offers three-pronged benefits when administered as a vehicle for obesity treatment. It augments weight management by boosting gradual weight loss, progressively improving weight maintenance and reducing chances of comorbidities in overweight people. Clinical trials have proven the role of Sibutramine Hydrochloride as an effective adjunct to diet and exercise in weight management.

How does Sibutramine work?

The clinical influences of Sibutramine hydrochloride Monohydrate are explained through its known mechanism of action as a serotonin and noradrenaline reuptake inhibitor (SNRI). This dual mechanism of action further results in dual synergistic physiological effects, that is, a decrease in energy ingestion and an increase in energy egestion. This combined action of Sibutramine Hydrochloride promotes as well as maintains weight loss.

Science behind Sibutramine Hydrochloride reveals that Sibutramine is rapidly absorbed from the gastrointestinal tract following oral administration and is then metabolized in the liver to form active mono- and di-desmethyl metabolites. It is largely metabolized in the liver by the cytochrome isoenzyme, to desmethyl metabolites which are further metabolized by hydroxylation and conjugation of inactive metabolites, following oral administration of Sibutramine Hydrochloride.

The metabolites in plasma concentrations reach a steady-state within four days of dosing and are something like two-fold higher than after a single dose. The elimination half-lives of the metabolites are 14-16 hours, which remain unchanged following repeated dosing.

Approximately 85% of a single orally administered dose is excreted in the urine and feces over a 15-day collection period with the majority of the dose (77%) excreted in the urine. Its primary route of excretion is through hepatic metabolism in urine and through renal excretion in the faeces.

To cut a long story short, Sibutramine is seen to be well tolerated as well as effective in obesity management. The inclusion of Sibutramine hydrochloride did not result in an adverse increase in blood pressure. However, based on the potential for changes in BP and PR, obesity treatment with Sibutramine should be monitored periodically for these changes.